Skip to main content
SpringerLink
Log in

Aripiprazole is the STAR for cost effectiveness in schizophrenia

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aripiprazole is the STAR for cost effectiveness in schizophrenia. Pharmacoecon. Outcomes News 621, 5 (2011). https://doi.org/10.2165/00151234-201106210-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-201106210-00010

Keywords

Search

Navigation